Kohei Hanaoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kohei Hanaoka has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Makoto Hosono
Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Osaka, Japan
3 shared publications - Kenta Sakaguchi
Radiology Center, Kindai University Hospital, Sakai, Japan
2 shared publications - Sung-Woon Im
Department of Radiology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
2 shared publications - Hajime Monzen
Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osaka, Japan
1 shared publication Hideo Morimoto
1 shared publicationHirokuni Yamanishi
1 shared publication
Latest Publications
- Open Access
- 1 July 2019
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 1 (1)
Registration accuracy with the low dose kilovoltage cone-beam CT: A phantom study
The aim of this study was to investigate low-dose kilovoltage cone-beam CT (kV-CBCT) for image-guided radiotherapy, with a particular focus on the accuracy of image registration with low-dose protocols. Imaging doses were measured with a NOMEX semiconductor detector positioned at the front of head, thorax, and pelvis human body phantoms while kV-CBCT scans were acquired at different tube currents. Aspects of image quality (spatial resolution, noise, uniformity, contrast, geometric distortion, and Hounsfield unit sensitivity) and image registration accuracy using bone and soft tissue were evaluated. With preset and the lowest tube currents, the imaging doses were 0.16 and 0.08 mGy, 5.29 and 2.80 mGy, and 18.23 and 2.69 mGy for head, thorax, and pelvis, respectively. Noise was the only quality aspect directly dependent on tube current, being increased by 1.5 times with a tube current half that of the preset in head and thorax, and by 2.2 times with a tube current 1/8 of the preset in the pelvis. Accurate auto-bone matching was performed within 1 mm at the lowest tube current. The auto-soft tissue matching could not be performed with the lowest tube current; however, manual-soft tissue matching could still be performed within 2 mm or less. Noise was the only image quality aspect dependent on the imaging dose. Auto-bone and manual-soft tissue matching could still be performed at the lowest imaging dose. When optimizing kV-CBCT imaging dose, the impact on bone and soft tissue image registration accuracy should be evaluated.
- 1 July 2019
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 1 (1)
Open AccessRegistration accuracy with the low dose kilovoltage cone-beam CT: A phantom study
The aim of this study was to investigate low-dose kilovoltage cone-beam CT (kV-CBCT) for image-guided radiotherapy, with a particular focus on the accuracy of image registration with low-dose protocols. Imaging doses were measured with a NOMEX semiconductor detector positioned at the front of head, thorax, and pelvis human body phantoms while kV-CBCT scans were acquired at different tube currents. Aspects of image quality (spatial resolution, noise, uniformity, contrast, geometric distortion, and Hounsfield unit sensitivity) and image registration accuracy using bone and soft tissue were evaluated. With preset and the lowest tube currents, the imaging doses were 0.16 and 0.08 mGy, 5.29 and 2.80 mGy, and 18.23 and 2.69 mGy for head, thorax, and pelvis, respectively. Noise was the only quality aspect directly dependent on tube current, being increased by 1.5 times with a tube current half that of the preset in head and thorax, and by 2.2 times with a tube current 1/8 of the preset in the pelvis. Accurate auto-bone matching was performed within 1 mm at the lowest tube current. The auto-soft tissue matching could not be performed with the lowest tube current; however, manual-soft tissue matching could still be performed within 2 mm or less. Noise was the only image quality aspect dependent on the imaging dose. Auto-bone and manual-soft tissue matching could still be performed at the lowest imaging dose. When optimizing kV-CBCT imaging dose, the impact on bone and soft tissue image registration accuracy should be evaluated.
- 25 April 2018
- Published by Springer Nature
- p. 99-104
Resistance and Heterogeneity of Intratumoral Antibody Distribution
- 25 April 2018
- Published by Springer Nature
- p. 99-104
Resistance and Heterogeneity of Intratumoral Antibody Distribution
- Open Access
- 14 March 2015
- Published by Springer Nature in EJNMMI Research
- Vol. 5 (1) , 10
Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of 111In-ibritumomab tiuxetan (Zevalin®) and tumor accumulation of 18F-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin’s lymphoma patients receiving 90Y-ibritumomab tiuxetan (Zevalin®) therapy. Methods: Sixteen patients with histologically confirmed non-Hodgkin’s B-cell lymphoma who underwent 90Y-ibritumomab tiuxetan therapy along with 111In-ibritumomab tiuxetan single-photon emission computerized tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of 111In-ibritumomab tiuxetan were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and 111In-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images. Results: A positive correlation was observed between the FDG SUVmax and accumulation of 111In-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in 111In-ibritumomab tiuxetan SUVmax was observed between the two groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices between responders and non-responders, while 111In-ibritumomab tiuxetan demonstrated skewness of 0.58 ± 0.16 and 0.73 ± 0.24 (p < 0.05), kurtosis of 2.39 ± 0.32 and 2.78 ± 0.53 (p < 0.02), and AUC-CSH of 0.37 ± 0.04 and 0.34 ± 0.05 (p < 0.05) for responders and non-responders. Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in 90Y-ibritumomab tiuxetan therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of 111In-ibritumomab tiuxetan was correlated with the tumor response.
- 14 March 2015
- Published by Springer Nature in EJNMMI Research
- Vol. 5 (1) , 10
Open AccessHeterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of 111In-ibritumomab tiuxetan (Zevalin®) and tumor accumulation of 18F-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin’s lymphoma patients receiving 90Y-ibritumomab tiuxetan (Zevalin®) therapy. Methods: Sixteen patients with histologically confirmed non-Hodgkin’s B-cell lymphoma who underwent 90Y-ibritumomab tiuxetan therapy along with 111In-ibritumomab tiuxetan single-photon emission computerized tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of 111In-ibritumomab tiuxetan were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and 111In-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images. Results: A positive correlation was observed between the FDG SUVmax and accumulation of 111In-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in 111In-ibritumomab tiuxetan SUVmax was observed between the two groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices between responders and non-responders, while 111In-ibritumomab tiuxetan demonstrated skewness of 0.58 ± 0.16 and 0.73 ± 0.24 (p < 0.05), kurtosis of 2.39 ± 0.32 and 2.78 ± 0.53 (p < 0.02), and AUC-CSH of 0.37 ± 0.04 and 0.34 ± 0.05 (p < 0.05) for responders and non-responders. Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in 90Y-ibritumomab tiuxetan therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of 111In-ibritumomab tiuxetan was correlated with the tumor response.
- 1 January 2013
- Published by Japan Radioisotope Association in RADIOISOTOPES
- Vol. 62 (9) , 659-665
Measurements for a Contamination Control of a 223Ra Medicament
- 1 January 2013
- Published by Japan Radioisotope Association in RADIOISOTOPES
- Vol. 62 (9) , 659-665
Measurements for a Contamination Control of a 223Ra Medicament